Profile: Aerpio Pharmaceuticals Inc (ARPO.OQ)
14 Jun 2019
Aerpio Pharmaceuticals, Inc., incorporated on November 16, 2007, is a biopharmaceutical company. The Company is focused on developing treatments for ocular disease. Its lead product candidate is AKB-9778. Its other two pipeline programs include AKB-4924 and ARP-1536.
AKB-9778 is a small molecule activator of the Tie-2 pathway, which is being developed for the treatment of diabetic retinopathy (DR). AKB-9778 helps to stabilize blood vessel walls and prevent leaks in the eye. AKB-9778 is being developed as a self-administered subcutaneous injection. AKB-9778 works by inhibiting VE-PTP, an enzyme that is up regulated in diabetic eye disease and that is responsible for inactivating Tie-2. As of April 14, 2017, the Company had completed a Phase II trial of AKB-9778 in 144 patients with diabetic macular edema.
AKB-4924 is a selective stabilizer of hypoxia-inducible factor-1 alpha (HIF-1alpha), which is being developed for the treatment of inflammatory bowel disease (IBD). AKB-4924 belongs to a group of compounds known as prolyl hydroxylase inhibitors. AKB-4924 works by inhibiting hypoxia-inducible factor (HIF) prolyl-hydroxylase enzymes. As of April 14, 2017, the Company had completed Phase Ia clinical trial in healthy volunteers for AKB-4924.
ARP-1536 is a humanized monoclonal antibody directed at the same target as AKB-9778. ARP-1536 binds the extracellular domain of vascular endothelial protein tyrosine phosphatase (VE-PTP) inhibiting its ability to interact with Tie-2. ARP-1536 is currently in preclinical development and may be developed for wet age-related macular degeneration and diabetic macular edema (DME).
Aerpio Pharmaceuticals Inc
9987 Carver Rd
BLUE ASH OH 45242-5550